The Human Microbiome Sequencing Market is expected to grow at a 20.8% CAGR during the forecasting period of 2024-2031.
The group of microbes that live on and in our bodies is known as the human microbiome. The human microbiota, a collective term for the billions of microorganisms that cover human tissues, includes bacteria, fungi, and viruses. The term "microbiome" refers to all of these microorganisms' genes. The human body has so many of these microorganisms that they comprise about 2-3 kg of weight. As human microbiome research develops, it is becoming clear that imbalances in gut microbiota may play a role in various non-communicable diseases, including gastrointestinal inflammation, metabolic issues, and potentially cardiovascular, pulmonary, and neurological conditions.
Numerous medical conditions, such as obesity, inflammatory bowel disease, diabetes, and others, may be treated by microbiomes. The human microbiome sequencing market is strongly influenced by the increasing prevalence of lifestyle-related diseases worldwide because therapeutics may offer an alternative approach to addressing important healthcare issues like obesity, autoimmune disorders, genomic disorders, gastrointestinal diseases, antibiotic resistance, cancer, Crohn's syndrome, and bowel syndrome. The market for human microbiome sequencing services is expanding due to the increasing number of cancer cases worldwide.
However, it is anticipated that the human microbiome sequencing industry will not expand due to a lack of knowledge and insufficient research. Additionally, barriers to establishing a causal connection between dysbiosis and diseases, a lack of favourable reimbursement scenarios and technology penetration in developing economies, and an inadequate infrastructure in low- and middle-income nations are all anticipated to pose challenges to the market during the forecast period.
The human microbiome sequencing market is segmented on the basis of product type, technology, application, and end-user. Based on product type, the market is differentiated into kits and assays, instruments, and software. Based on technology, the market is segmented into next-generation sequencing (Sequencing by Synthesis, Sequencing by Ligation and Other Next-Generation Sequencing Technologies), traditional sequencing technologies (Pyrosequencing and Sanger Sequencing) and other sequencing technology. Based on application, the market is differentiated into disease diagnosis (Gastrointestinal Diseases, Metabolic Diseases, Oncology, Infectious Diseases, Neurological Diseases and Other Diseases), drug discovery, consumer wellness, omics analysis (Genome Analysis, Metabolome Analysis, Transcriptome Analysis and Other Omics Analysis) and other application. Based on end-user, the market is differentiated into research and academic institutions, pharmaceutical and biotechnology companies, and other end users.
The drug discovery category holds the largest market share in the forecast period. The significant share of this sector can be ascribed to the expansion of novel drug discovery research initiatives as well as market participants, academic institutions, and pharmaceutical firms' drug development partnerships. In the past twenty years, the pharmaceutical business has seen a significant transformation, including a shift toward biologics, the expiration of patents, and a remarkable reduction in the internal discovery of large-scale medications. The acceptance of outsourcing drug discovery initiatives has accelerated due to everything. The pharmaceutical industry's increasing expenditure on creating novel pharmaceuticals and clinical trial research is fuelling the expansion of the global drug discovery sector.
Next-generation sequencing (NGS) refers to the extensive DNA sequencing techniques supporting genomic research. A wide range of reputable pharmaceutical and biotechnology businesses have agreed to step up to support the global research efforts to create test kits and vaccinations in the wake of the World Health Organization's (WHO) declaration of COVID-19 as a pandemic. The widespread usage of Next- Generation Sequencing (NGS) technologies due to their high efficiency and low cost are some of the main drivers propelling the growth of the Next- Generation Sequencing (NGS), along with ongoing technological advancements in sequencers. Growing technological advances in NGS equipment and technologies are also anticipated to contribute to a sizable segment size increase in the following years.
The North American human microbiome sequencing market is expected to grow faster than average due to the increasing usage of highly advanced techniques and systems in human microbiome sequencing and technological advancements in genomic research investigations. The substantial regional market growth is primarily due to the high awareness among medical professionals about the existence of cutting-edge human microbiome sequencing services in the market. The massive number of people affected by cancer and the growing demand for microbiome sequencing services for the convenience of such diseases' diagnosis and treatment is anticipated to fuel the market's expansion in the coming years. Thus, it is well known that the rising demand for human microbiome sequencing and rising investment in the health care sector are driving the market's expansion in this area.
In addition, Asia-Pacific is predicted to experience significant growth during the forecast period due to increased government initiatives to raise awareness, a rise in medical tourism, expanding research activities in the region, rising incidences of lifestyle-related diseases and autoimmune disorders, and rising demand for high-quality healthcare in the area. Additionally, the market may expand due to the rising prevalence of illnesses that lower quality of life and the expansion of the healthcare industry.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 20.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product Type, Technology, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., and Molzym GmbH & Co. KG.. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Human Microbiome Sequencing Market Snapshot
Chapter 4. Global Human Microbiome Sequencing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product Type:
5.2.1. Kits and Assays
5.2.2. Instruments
5.2.3. Software
Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
6.2.1. Next-Generation Sequencing
6.2.2. Sequencing by Synthesis
6.2.3. Sequencing by Ligation
6.2.4. Other Next-Generation Sequencing Technologies
6.2.5. Traditional Sequencing Technologies
6.2.6. Pyrosequencing
6.2.7. Sanger Sequencing
6.2.8. Other Sequencing Technology
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Disease Diagnoses
7.2.2. Gastrointestinal Diseases
7.2.3. Metabolic Diseases
7.2.4. Oncology
7.2.5. Infectious Diseases
7.2.6. Neurological Diseases
7.2.7. Other Diseases
7.2.8. Drug Discovery
7.2.9. Consumer Wellness
7.2.10. Omics Analysis
7.2.11. Genome Analysis
7.2.12. Metabolome Analysis
7.2.13. Transcriptome Analysis
7.2.14. Other Omics Analysis
7.2.15. Other Application
Chapter 8. Market Segmentation 4: by End-user Estimates & Trend Analysis
8.1. by End-user & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-user:
8.2.1. Research and Academic Institutions
8.2.2. Pharmaceutical and Biotechnology Companies
8.2.3. Other End Users
Chapter 9. Human Microbiome Sequencing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Human Microbiome Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
9.1.2. North America Human Microbiome Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
9.1.3. North America Human Microbiome Sequencing Market revenue (US$ Million) by Application, 2024-2031
9.1.4. North America Human Microbiome Sequencing Market revenue (US$ Million) by End-user, 2024-2031
9.1.5. North America Human Microbiome Sequencing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe Human Microbiome Sequencing Market revenue (US$ Million) by Product Type, 2024-2031
9.2.2. Europe Human Microbiome Sequencing Market revenue (US$ Million) by Technology, 2024-2031
9.2.3. Europe Human Microbiome Sequencing Market revenue (US$ Million) by Application, 2024-2031
9.2.4. Europe Human Microbiome Sequencing Market revenue (US$ Million) by End-user, 2024-2031
9.2.5. Europe Human Microbiome Sequencing Market revenue (US$ Million) by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Human Microbiome Sequencing Market revenue (US$ Million) by Product Type, 2024-2031
9.3.2. Asia Pacific Human Microbiome Sequencing Market revenue (US$ Million) by Technology, 2024-2031
9.3.3. Asia-Pacific Human Microbiome Sequencing Market revenue (US$ Million) by Application, 2024-2031
9.3.4. Asia Pacific Human Microbiome Sequencing Market revenue (US$ Million) by End-user, 2024-2031
9.3.5. Asia Pacific Human Microbiome Sequencing Market revenue (US$ Million) by country, 2024-2031
9.4. Latin America
9.4.1. Latin America Human Microbiome Sequencing Market revenue (US$ Million) by Product Type, 2024-2031
9.4.2. Latin America Human Microbiome Sequencing Market revenue (US$ Million) by Technology, 2024-2031
9.4.3. Latin America Human Microbiome Sequencing Market revenue (US$ Million) by Application, 2024-2031
9.4.4. Latin America Human Microbiome Sequencing Market revenue (US$ Million) by End-user, 2024-2031
9.4.5. Latin America Human Microbiome Sequencing Market revenue (US$ Million) by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Human Microbiome Sequencing Market revenue (US$ Million) by Product Type, 2024-2031
9.5.2. Middle East & Africa Human Microbiome Sequencing Market revenue (US$ Million) by Technology, 2024-2031
9.5.3. Middle East & Africa Human Microbiome Sequencing Market revenue (US$ Million) by Application, 2024-2031
9.5.4. Middle East & Africa Human Microbiome Sequencing Market revenue (US$ Million) by End-user, 2024-2031
9.5.5. Middle East & Africa Human Microbiome Sequencing Market revenue (US$ Million) by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Baseclear B.V.
10.2.2. Beijing Genomics Institute (BGI) Genomics Co., Ltd
10.2.3. Charles River Laboratories International Inc.
10.2.4. Clinical Microbiomics A/S
10.2.5. Eurofins Scientific SE
10.2.6. GENEWIZ, Inc.
10.2.7. Illumina, Inc.
10.2.8. Novogene Corporation
10.2.9. OraSure Technologies, Inc.
10.2.10. Oxford Nanopore Technologies, Inc.
10.2.11. Pacific Biosciences of California, Inc.
10.2.12. QIAGEN N.V.
10.2.13. Second Genome, Inc.
10.2.14. Thermo Fisher Scientific Inc.
10.2.15. Viome, Inc.
10.2.16. CosmosID
10.2.17. Leucine Rich Bio Pvt. Ltd.
10.2.18. Microba
10.2.19. Microbiome Insights Inc.
10.2.20. Molzym GmbH & Co. KG
10.2.21. Other Prominent Players
By Product Type
By Technology
By Application
By End User
By Region-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
